Brucellosis is a systemic zoonotic infection caused by intracellular gram-negative coccobacilli of the genus Brucella, often called one of the "great imitators" alongside syphilis and tuberculosis due to its protean clinical manifestations. [1] It is the most common zoonotic infection worldwide, affecting approximately 500,000 people annually. [2-3]
1. History
- Exposure history is the diagnostic cornerstone: Ask specifically about contact with livestock (cattle, sheep, goats, pigs), consumption of unpasteurized dairy products (milk, cheese, yogurt), and occupational exposure (farmers, veterinarians, slaughterhouse workers, laboratory personnel) [1][4]
- Symptom characterization: Undulant fever pattern (classically rising in the afternoon/evening), drenching sweats (often described as foul-smelling), profound fatigue, arthralgias/myalgias, anorexia, weight loss [5-6]
- Timing: Incubation period typically 2–4 weeks (range 1 week to several months); acute (<8 weeks), subacute (8–52 weeks), chronic (>12 months) [5]
- Associated symptoms: Low back pain, testicular pain/swelling (males), headache, depression, abdominal pain, cough [7-8]
- Important negatives: Travel to endemic regions (Middle East, Mediterranean, Central/South America, sub-Saharan Africa, Indian subcontinent); recent immigration status [3]
2. Alarm Features
- Endocarditis — the most lethal complication, accounting for >80% of brucellosis-related deaths despite occurring in <2% of cases; aortic valve most commonly affected [1][7]
- Neurobrucellosis (meningoencephalitis, cranial nerve palsies, myelitis) — occurs in 4–7% of cases [2]
- Spondylodiscitis with epidural/paraspinal abscess — back pain with neurological deficits [9]
- Splenic abscess or rupture
- Severe pancytopenia mimicking hematologic malignancy
- New cardiac murmur in a febrile patient with risk factors should prompt urgent echocardiography [7]
3. Medications
- First-line (gold standard): Doxycycline 100 mg PO BID × 6 weeks + Streptomycin 1 g IM daily × 2–3 weeks [5][10]
- Alternative dual therapy: Doxycycline 100 mg PO BID + Rifampin 600–900 mg PO daily, both × 6 weeks (easier to administer but higher relapse rate) [5][10]
- Triple therapy for complicated disease: Doxycycline + Rifampin + Levofloxacin (or streptomycin) × 12 weeks — shown to reduce treatment failure and relapse compared to dual therapy [6][11]
- Neurobrucellosis/endocarditis: Doxycycline + Rifampin + Ceftriaxone (CNS-penetrating regimen); prolonged courses (3–6 months) [2]
- Children <8 years: TMP-SMX + Rifampin × 6 weeks (avoid tetracyclines) [3][12]
- Pregnancy: Rifampin ± TMP-SMX (avoid doxycycline and aminoglycosides) [12]
- Cautions: Rifampin reduces serum doxycycline levels and has extensive drug-drug interactions (warfarin, OCP, calcineurin inhibitors); monotherapy is never recommended due to unacceptable relapse rates [5][10]
4. Diet
- Strict avoidance of unpasteurized dairy products (milk, soft cheeses, yogurt) — the most common mode of transmission [1-2]
- Avoid undercooked meat from potentially infected animals
- Adequate hydration and nutritional support during acute illness — brucellosis causes significant protein/albumin depletion (hypoalbuminemia in up to 92% of cases) [4]
- No specific long-term dietary restrictions beyond food safety practices
5. Review of Systems
- Constitutional: Fever pattern, night sweats, weight loss, fatigue, malaise [5]
- Musculoskeletal: Joint pain (especially sacroiliac, hip, knee), low back pain, difficulty ambulating [8]
- GI: Abdominal pain, nausea, vomiting, hepatitis symptoms [7]
- GU: Testicular pain/swelling (epididymo-orchitis in 2–20% of males) [7]
- Neuropsychiatric: Headache, depression, lethargy, confusion, hearing loss [2][5]
- Respiratory: Cough, dyspnea (pneumonia/pleural effusion in up to 16% of complicated cases) [1]
- Cardiovascular: Chest pain, dyspnea on exertion (endocarditis screening)
- Dermatologic: Rash (erythematous papules, purpura — uncommon) [1]
6. Collateral History and Family History
- Household contacts: Other family members consuming the same unpasteurized dairy products or with animal exposure should be screened [1]
- Occupational clusters: Co-workers in farming, veterinary, or laboratory settings
- Travel companions who shared food exposures
- No hereditary predisposition, but familial clustering is common due to shared dietary/occupational exposures [13]
- Social context: Immigration from endemic areas; cultural practices involving raw dairy consumption
7. Risk Factors
- Occupational: Farmers, shepherds, veterinarians, slaughterhouse workers, laboratory personnel (BSL-3 pathogen) [1][4]
- Dietary: Consumption of unpasteurized milk, soft cheese, or other raw dairy products (71% of cases in one US outbreak) [13]
- Animal contact: Direct contact with cattle, sheep, goats, pigs, or their birthing products [4]
- Geographic: Endemic in the Middle East, Mediterranean basin, Central/South America, sub-Saharan Africa, Indian subcontinent, Central Asia [3]
- Demographics: Males affected 2–3× more than females; peak age 30–69 years [4]
- Immunosuppression: Transplant recipients, HIV (rare but more severe) [3]
8. Differential Diagnosis
- Tuberculosis — overlapping symptoms (fever, sweats, weight loss, spondylitis); both endemic in similar regions; distinguish by PPD/IGRA, AFB cultures, imaging patterns [1]
- Infective endocarditis (other causes) — if new murmur present
- Lymphoma/leukemia — pancytopenia, hepatosplenomegaly, B symptoms
- Typhoid/enteric fever — similar undulant fever, travel history; blood cultures differentiate
- Q fever (Coxiella burnetii) — similar zoonotic exposure, hepatitis, endocarditis risk
- Rheumatic fever / reactive arthritis — migratory arthritis, fever
- Visceral leishmaniasis — hepatosplenomegaly, pancytopenia, fever in endemic overlap areas
- HIV seroconversion — fever, lymphadenopathy, constitutional symptoms
- Systemic lupus erythematosus — multisystem involvement, cytopenias
- Vertebral osteomyelitis (pyogenic) — if spondylitis is the presenting feature [9]
9. Past Medical History
- Prior episodes of brucellosis (relapse rate 5–13%) [4][6]
- Valvular heart disease (increases endocarditis risk) [7]
- Immunosuppressive conditions or medications
- Splenectomy (impaired clearance of intracellular organisms)
- Prior TB treatment (rifampin resistance concerns) [10]
- Chronic liver disease (hepatotoxicity risk with rifampin)
- Renal impairment (aminoglycoside dosing adjustments)
10. Physical Exam
- Vital signs: Fever (often undulant pattern, 64–93% of cases), tachycardia; typically hemodynamically stable unless complicated [6][8]
- Hepatomegaly (~30% of patients) and splenomegaly (~26–34%) [1][6]
- Lymphadenopathy (~10%) [1]
- Musculoskeletal: Sacroiliac joint tenderness (FABER test), spinal tenderness (especially lumbar), peripheral joint effusions, limited range of motion [8-9]
- GU: Testicular swelling/tenderness (epididymo-orchitis) [7]
- Cardiac: Auscultate carefully for new murmurs (endocarditis) [7]
- Neurological: Meningismus, cranial nerve deficits, peripheral neuropathy signs (if neurobrucellosis suspected) [2]
- Skin: Erythematous papular lesions, purpura (uncommon) [1]
11. Lab Studies
- Blood cultures (gold standard for definitive diagnosis) — sensitivity 15–70%; use automated systems with extended incubation (≥7 days); notify lab of suspicion (BSL-3 organism) [10][14]
- Bone marrow culture — highest sensitivity, considered the true gold standard but invasive [10]
- Serology:
- Rose Bengal Test (RBT) — rapid screening, high sensitivity [1]
- Standard Tube Agglutination (SAT) — titers ≥1:160 diagnostic (≥1:320 in endemic areas) [10]
- ELISA (IgG + IgM) — sensitivity up to 98.7%, increasingly preferred [15]
- Brucellacapt — excellent specificity (100%) [16]
- CBC: Leukopenia (11%), thrombocytopenia (10%), anemia (26%); leukocytosis is uncommon and should prompt search for focal complications [1]
- Inflammatory markers: Elevated ESR (up to 88%), elevated CRP (40–78%) [4][9]
- LFTs: Elevated ALT/AST (20–33% of cases) — hepatic granulomas common [17]
- Albumin/total protein: Often decreased (hypoalbuminemia in up to 92%) [4]
- Procalcitonin: May be elevated in bacteremic cases [18]
12. Imaging
- First-line: Plain radiographs of affected joints/spine (may be normal early)
- MRI of the spine — gold standard for brucellar spondylitis; findings include disc space narrowing, vertebral endplate erosion, paraspinal/epidural abscess; lumbar spine (especially L4/5) most commonly affected [8-9]
- Ultrasound: Hepatosplenomegaly assessment; scrotal ultrasound for epididymo-orchitis
- Echocardiography (TTE → TEE): Mandatory if endocarditis suspected (new murmur, persistent bacteremia, embolic phenomena) [7]
- CT abdomen/pelvis: Splenic abscess, hepatic abscess evaluation
- Chest X-ray: If respiratory symptoms present (pneumonia, pleural effusion)
- Imaging is unnecessary in uncomplicated acute brucellosis responding to treatment
13. Special Tests
- PCR/nucleic acid amplification: High sensitivity and specificity for rapid diagnosis; however, may remain positive after clinical cure, limiting utility for treatment monitoring [14]
- Coombs' anti-Brucella test: Detects non-agglutinating (blocking) antibodies; useful in chronic/relapsing cases where SAT may be falsely negative [1]
- 2-mercaptoethanol (2-ME) test: Differentiates IgM from IgG; persistent IgG suggests active/chronic infection
- Arthrocentesis: If septic arthritis suspected — send for culture and cell count
- Lumbar puncture: If neurobrucellosis suspected — CSF shows lymphocytic pleocytosis, elevated protein, low glucose; send for Brucella culture and PCR [2]
14. ECG
- Indications: Obtain ECG if endocarditis is suspected or if the patient has chest pain, dyspnea, or new murmur
- Findings: Conduction abnormalities (AV block, bundle branch block) may indicate perivalvular abscess in Brucella endocarditis
- Pericarditis: Diffuse ST elevation, PR depression (rare complication)
- Routine ECG not required in uncomplicated brucellosis
15. Assessment
Brucellosis is a multisystem intracellular infection with highly variable, nonspecific presentation. A high index of suspicion driven by epidemiologic exposure is essential for timely diagnosis. [1][19] Key clinical pearls:
- The classic triad is fever + sweats + arthralgias in a patient with animal/dairy exposure
- Classified as acute (<8 weeks), subacute (8–52 weeks), or chronic (>12 months) [5]
- Osteoarticular complications are the most common focal manifestation (~34–50%) [8][20]
- Endocarditis, though rare (<2%), is responsible for the majority of deaths [7]
- Risk factors for poor prognosis: age ≥45, back pain, joint tenderness, delayed diagnosis [17]
- Relapse rate is 5–13% even with appropriate therapy [4][6]
16. Treatment Plan
Initial stabilization
- Hemodynamic support if septic; IV fluids, antipyretics
- Notify microbiology lab of Brucella suspicion (biosafety precautions)
Antibiotic regimens
Key treatment pearls
- Triple therapy (adding streptomycin or levofloxacin to doxycycline + rifampin) significantly reduces treatment failure (RR 1.98–2.98 for dual vs. triple) and relapse rates [11]
- Doxycycline + streptomycin is superior to doxycycline + rifampin for preventing relapse [5][21]
- Monotherapy is never acceptable [10]
- Gentamicin (5 mg/kg/day × 5–7 days) may substitute for streptomycin [12]
17. Disposition
Admission criteria
- Endocarditis or suspected endocarditis
- Neurobrucellosis (meningitis, encephalitis, focal neurological deficits)
- Severe sepsis/bacteremia with hemodynamic instability
- Spondylitis with epidural abscess or neurological compromise
- Significant cytopenias (severe anemia, thrombocytopenia)
- Need for parenteral aminoglycoside therapy without outpatient infrastructure
- Inability to tolerate oral medications
Discharge/outpatient criteria
- Uncomplicated acute brucellosis in a hemodynamically stable patient
- Able to tolerate oral medications and follow up reliably
- No evidence of focal complications on initial workup
Specialist consultation triggers
- Infectious disease — all confirmed/suspected cases
- Cardiothoracic surgery — if endocarditis with valve destruction
- Neurosurgery — epidural abscess with cord compression
- Orthopedics — septic arthritis requiring drainage
- Public health notification — brucellosis is a reportable disease in most jurisdictions
18. Follow Up / Return Precautions
- Follow-up timing: Clinical reassessment at 2 weeks, then monthly during treatment; serologic follow-up (SAT titers) at 3, 6, and 12 months post-treatment to monitor for relapse [14]
- Expected course: Fever typically resolves within 1–2 weeks of appropriate therapy; fatigue and arthralgias may persist for weeks to months
- Return precautions — seek immediate care for:
- Recurrence of fever or sweats after initial improvement
- New or worsening joint pain, back pain, or neurological symptoms
- Chest pain, dyspnea, or new cardiac symptoms
- Testicular swelling or pain
- Severe headache, neck stiffness, or altered mental status
- Patient counseling: Complete the full antibiotic course (premature discontinuation is the leading cause of relapse); avoid unpasteurized dairy products permanently; educate household contacts about screening [1][13]
- Relapse: Occurs in 5–13% of cases, typically within 6 months of completing therapy; requires retreatment with a different or intensified regimen [4][6]
References
1. Human Brucellosis. — Franco MP, Mulder M, Gilman RH, Smits HL. The Lancet. Infectious Diseases. 2007.
2. Brucellosis. — Shakir R. Journal of the Neurological Sciences. 2021.
3. Endemic or Regionally Limited Bacterial and Viral Infections in Haematopoietic Stem-Cell Transplantation Recipients: A Worldwide Network for Blood and Marrow Transplantation (WBMT) Review. — Muhsen IN, Galeano S, Niederwieser D, et al. The Lancet. Haematology. 2023.
4. Epidemiology, Clinical Manifestations, and Laboratory Findings of 1,590 Human Brucellosis Cases in Ningxia, China. — Liu B, Liu G, Ma X, et al. Frontiers in Microbiology. 2023.
5. Antibiotics for Treating Human Brucellosis. — Yousefi-Nooraie R, Mortaz-Hejri S, Mehrani M, Sadeghipour P. The Cochrane Database of Systematic Reviews. 2012.
6. The Clinical Features of 590 Patients With Brucellosis in Xinjiang, China With the Emphasis on the Treatment of Complications. — Jia B, Zhang F, Lu Y, et al. PLoS Neglected Tropical Diseases. 2017.
7. Research Progress on Complications of Rucellosis. — Jin M, Fan Z, Gao R, et al. Frontiers in Cellular and Infection Microbiology. 2023.
8. Epidemiological Characteristics, Clinical Manifestations and Laboratory Findings in 850 Patients With Brucellosis in Heilongjiang Province, China. — Jiang W, Chen J, Li Q, et al. BMC Infectious Diseases. 2019.
9. Epidemiology and Laboratory Testing of Brucella Spondylitis. — Lu YP, Qiu WQ, Zhang T, et al. Scientific Reports. 2024.
10. Brucellosis. — Pappas G, Akritidis N, Bosilkovski M, Tsianos E. The New England Journal of Medicine. 2005.
11. A Systematic Review and Meta-Analysis of Comparative Clinical Studies on Antibiotic Treatment of Brucellosis. — Maduranga S, Valencia BM, Li X, Moallemi S, Rodrigo C. Scientific Reports. 2024.
12. Recognition and Optimum Treatment of Brucellosis. — Solera J, Martínez-Alfaro E, Espinosa A. Drugs. 1997.
13. An Outbreak of Brucellosis: An Adult and Pediatric Case Series. — Hassouneh L, Quadri S, Pichilingue-Reto P, et al. Open Forum Infectious Diseases. 2019.
14. Laboratory Diagnosis of Human Brucellosis. — Yagupsky P, Morata P, Colmenero JD. Clinical Microbiology Reviews. 2019.
15. ELISA Is Superior to Bacterial Culture and Agglutination Test in the Diagnosis of Brucellosis in an Endemic Area in China. — Xu N, Wang W, Chen F, Li W, Wang G. BMC Infectious Diseases. 2020.
16. Evaluating the Efficacy of Serological Testing of Clinical Specimens Collected From Patients With Suspected Brucellosis. — Xu N, Qu C, Sai L, et al. PLoS Neglected Tropical Diseases. 2023.
17. Clinical Features of 2041 Human Brucellosis Cases in China. — Shi Y, Gao H, Pappas G, et al. PloS One. 2018.
18. Blood Culture Positivity and Its Clinical Determinants Among Hospitalized Male Patients With Newly Diagnosed, Laboratory-Confirmed Brucellosis: A Hospital-Based Retrospective Study. — Han X, Zhang R, Xu B, et al. Frontiers in Microbiology. 2025.
19. Brucellosis: Epidemiology, Pathogenesis, Diagnosis and Treatment-a Comprehensive Review. — Qureshi KA, Parvez A, Fahmy NA, et al. Annals of Medicine. 2024.
20. Brucellosis: Evaluation of Two Hundred and Ten Cases With Different Clinical Features. — Eroglu E, Kandemir B. Annals of the Academy of Medicine, Singapore. 2020.
21. Efficacy and Safety of Therapeutic Strategies for Human Brucellosis: A Systematic Review and Network Meta-Analysis. — Silva SN, Cota G, Xavier DM, et al. PLoS Neglected Tropical Diseases. 2024.